IF YOU HAVE PREVIOUSLY REGISTERED FOR THIS EVENT, PLEASE LOG IN BELOW OR CLICK THE LINK ON THE EMAIL YOU RECEIVED:
MSD

Diabetes Digital Dialogues 2018

The Future of Digital Technology in the Treatment of Type 2 Diabetes Patients

Sethu Reddy

Sethu Reddy

Professor and Chair of Medicine, Central Michigan University College of Medicine, Mount Pleasant, Michigan, USA

Dr. Sethu Reddy is Senior Consultant and past-Chief of Adult Diabetes at JoslinDiabetes Center, Harvard, in Boston. He was previously Chairman of Endocrinology, Diabetes & Metabolism at Cleveland Clinic, currently ranked 2nd in the US by US News & World. He completed his undergraduate education at Memorial University of New foundlandand postgraduate training in Endocrinology & Metabolism at University of Toronto and in Molecular & Cellular Physiology at Joslin Diabetes Center, Harvard Medical School, Boston in 1988. Dr. Reddy has been actively involved in numerous clinically relevant projects with AACE since 1996 and is currently on the Board of Trustees for the American College of Endocrinology. In 2007, he received the distinction of Mastership in the American College of Endocrinology.

David Klonoff

David Klonoff

FELLOW AIMBE, Medical Director, Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, California, USA

David C. Klonoff, M.D. is an endocrinologist specializing in the development and use of diabetes technology. He is Medical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center in San Mateo, California and a Clinical Professor of Medicine at UCSF. Dr. Klonoff received an FDA Director’s Special Citation Award in 2010 for outstanding contributions related to diabetes technology. In 2012 Dr. Klonoff was elected as a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and cited as one of the 1000 top bioengineers in the world, as well as among the top 2% of the world’s bioengineers for his engineering work in diabetes technology. He received the 2012 Gold Medal Oration and Distinguished Scientist Award from the Dr. Mohan’s Diabetes Specialities Centre and Madras Diabetes Research Foundation of Chennai, India. Dr. Klonoff was invited to speak to the US Congressional Diabetes Caucus in 2017, participate in the White House Health and Cybersecurity Roundtable in 2015, and speak at the European Parliament in 2010. He is the Founding Editor-in-Chief of Journal of Diabetes Science and Technology. He has authored over 280 publications. Dr. Klonoff has been a Principal Investigator on over 110 clinical trials of diabetes drugs and devices, and has been lead investigator on multicenter trials for Novo, Sanofi, Medtronic, Biorad, and Diasome. He was the lead investigator for the first randomized controlled multicenter trial of an out patient artificial pancreas product, and published the results in the New England Journal of Medicine. He chaired the scientific advisory board for the first FDA-cleared insulin patch pump and participated in developing the first FDA-cleared dedicated diabetes telemedicine system.  Dr. Klonoff coined the term “diabetes technology” and founded the Diabetes Technology Meeting, the Digital Diabetes Congress, and the International Hospital Diabetes Meeting. Dr. Klonoff has chaired or served on 52 grant review panels including for NIH, CDC, NASA, NSF, US Army, NOAA, ADA, and JDRF; plus agencies in 7 foreign countries. He is a member of the Scientific Advisory Board of the Texas A&M/UCLA/FIU/Rice PATHS-UP Engineering Research Center and an affiliate member of the Baylor University Center for Space Medicine. Dr. Klonoff is a graduate of UC Berkeley, where he was elected to Phi Beta Kappa in his junior year, and UCSF Medical School, where he was elected to Alpha Omega Alpha in his junior year. His postgraduate training included two years at UCLA Hospital and three years at UCSF Hospitals. He is a member of the Healthcare Sector Coordinating Council Joint Cyber Working Group for Medical Devices/Healthcare. He chaired DTSec and DTMoST, the world’s 1st and 2nd consensus medical device cybersecurity standards. For this work Dr. Klonoff was featured in an article in Wired Magazine: https://www.wired.com/2015/11/the-doctor-on-a-quest-to-save-our-medical-devices-from-hackers/  


Laurel Pickering

Laurel Pickering

Executive Vice President of Enterprise Solutions for WellDoc Inc., Columbia, Maryland, USA

Laurel Pickering is the Executive Vice President of Enterprise Solutions for WellDoc and is responsible for managing and broadening relationships with key stakeholders to expand use of WellDoc’s FDA-cleared, proven BlueStar® digital therapeutic. Laurel is a leader and visionary, devoted to transforming healthcare at both regional and national levels. Before joining WellDoc, Laurel served as president & CEO of Northeast Business Group on Health (NEBGH) fornearly 25 years. There, she built an employer-led coalition of healthcare leaders and other stakeholders with the mission of empowering members to drive excellence and value in healthcare and the patient experience. NEBGH has 170 members comprised of national and global self-insured employers based in NewYork, New Jersey, Connecticut and Massachusetts; plus national health plans, major consulting organizations, regional hospital systems and other keystakeholders. Under Laurel’s leadership, NEBGH became one of the most activeand influential healthcare-focused business coalitions in the country, focusedon moving toward a value-based delivery system. Laurel serves on the Board of Directors of The Leapfrog Group and HealthPass. She is Co-Chair of the Advisory Council of the Center for Workplace Mental Health and Chair of the Appeals Board of the National Quality Forum (NQF). She previously served onthe Boards of the National Alliance of Health Care Purchaser Coalitions and NQF. Laurel received her BA in Anthropology from SUNY Albany and MPH from Emory University.


WEBCAST WILL BE TRANSMITTED LIVE ON: 
14 November 2018, 07:00 (EST), New Jersey (US)

WEBCAST WILL BE AVAILABLE ON DEMAND ON:
14 November 2018, 12:00 (EST), for 24 hours 

EST (Eastern Standard Time) or UTC -4 (Universal Time Coordinated)
Note: Times shown are equivalent across the globe – adjust your calendars to your preferred time zone. Customers can view the webcast in its entirety at any time during these time frames.


Agenda

Agenda


07:00-07:05 (5 minutes)

Welcome and Opening Remarks       

Sethu Reddy


07:05-07:25 (20 minutes)

The Future of Digital Technology in the Treatment of Type 2 Diabetes Patients

David Klonoff, Laurel Pickering


07:25-07:55 (30 minutes)

 Q&A

Sethu Reddy, David Klonoff, Laurel Pickering


07:55-08:00 (5 minutes)

Final Comments and Summary     

Sethu Reddy